Literature DB >> 28346318

Predictors of Impaired HDL Function in HIV-1 Infected Compared to Uninfected Individuals.

Theodoros Kelesidis1, Michael N Oda, Mark S Borja, Yumin Yee, Kit F Ng, Diana Huynh, David Elashoff, Judith S Currier.   

Abstract

OBJECTIVE: High-density lipoprotein (HDL) function rather than absolute level may be a more accurate indicator for cardiovascular disease (CVD). Novel methods can measure HDL function using patient samples. The objective of this study is to identify factors that may contribute to HDL dysfunction in chronic treated HIV-1 infection.
DESIGN: Retrospective study of HDL function measured in 2 ways in HIV-1-infected men with low overall CVD risk and healthy men with no known CVD risk matched by race to the HIV-1-infected participants.
METHODS: We examined patient-level factors associated with 2 different measures of HDL dysfunction: reduced antioxidant function (oxidized HDL, HDLox) and reduced HDL-apoA-I exchange (HAE), a measure of HDL remodeling, in the HIV infected and control men. Multivariable-adjusted linear regression analyses were used adjusting for false discovery rate, age, race, body mass index (BMI), CD4 count, viremia, CVD risk, smoking, lipids, apoA-I, and albumin.
RESULTS: In multivariate analysis among HIV-1-infected men (n = 166) (median age 45 years, CD4 T-cell count 505 cells/mm, 30.1% were viremic), higher BMI, lower apoA-I, and lower albumin were among the most notable correlates of higher HDLox and lower HAE (P < 0.05). In HIV-1 uninfected participants, lower albumin and higher BMI were associated with lower HAE and higher HDLox, respectively (P ≤ 0.05). HDLox was inversely related to HAE in HIV-1-infected individuals (P < 0.001).
CONCLUSIONS: Increased HDLox correlates with reduced HAE in chronic HIV-1 infection. Higher BMI, lower apoA-I, and albumin were identified as factors associated with HDL dysfunction in chronic HIV-1 infection using 2 independent methods.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28346318      PMCID: PMC5472482          DOI: 10.1097/QAI.0000000000001383

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  44 in total

Review 1.  The antioxidant properties of serum albumin.

Authors:  Marjolaine Roche; Philippe Rondeau; Nihar Ranjan Singh; Evelyne Tarnus; Emmanuel Bourdon
Journal:  FEBS Lett       Date:  2008-05-12       Impact factor: 4.124

2.  Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins.

Authors:  Giorgio Cavigiolio; Ethan G Geier; Baohai Shao; Jay W Heinecke; Michael N Oda
Journal:  J Biol Chem       Date:  2010-04-12       Impact factor: 5.157

Review 3.  High-density lipoprotein--the clinical implications of recent studies.

Authors:  D J Gordon; B M Rifkind
Journal:  N Engl J Med       Date:  1989-11-09       Impact factor: 91.245

4.  HDL cholesterol efflux capacity and incident cardiovascular events.

Authors:  Anand Rohatgi; Amit Khera; Jarett D Berry; Edward G Givens; Colby R Ayers; Kyle E Wedin; Ian J Neeland; Ivan S Yuhanna; Daniel R Rader; James A de Lemos; Philip W Shaul
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

5.  Effects of cigarette smoking on HDL quantity and function: implications for atherosclerosis.

Authors:  Bai-mei He; Shui-ping Zhao; Zhen-yu Peng
Journal:  J Cell Biochem       Date:  2013-11       Impact factor: 4.429

6.  Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.

Authors:  Grace A McComsey; Douglas Kitch; Eric S Daar; Camlin Tierney; Nasreen C Jahed; Kathleen Melbourne; Belinda Ha; Todd T Brown; Anthony Bloom; Neal Fedarko; Paul E Sax
Journal:  AIDS       Date:  2012-07-17       Impact factor: 4.177

Review 7.  Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones.

Authors:  Xuewen Wang; Faidon Magkos; Bettina Mittendorfer
Journal:  J Clin Endocrinol Metab       Date:  2011-04       Impact factor: 5.958

8.  Lipoprotein concentration, particle number, size and cholesterol efflux capacity are associated with mitochondrial oxidative stress and function in an HIV positive cohort.

Authors:  Nisha I Parikh; Mariana Gerschenson; Kara Bennett; Louie Mar M Gangcuangco; Mary S Lopez; Nehal N Mehta; Martin P Playford; Beau K Nakamoto; Todd B Seto; Dominic C Chow; Cecilia M Shikuma
Journal:  Atherosclerosis       Date:  2014-12-20       Impact factor: 5.162

Review 9.  The role of dysfunctional HDL in atherosclerosis.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2008-10-27       Impact factor: 5.922

10.  Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice.

Authors:  Junichiro Tohyama; Jeffrey T Billheimer; Ilia V Fuki; George H Rothblat; Daniel J Rader; John S Millar
Journal:  Atherosclerosis       Date:  2008-09-27       Impact factor: 5.162

View more
  8 in total

1.  Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein.

Authors:  Shubhendu Sen Roy; Huy Cong Xuan Nguyen; Thomas A Angelovich; Anna C Hearps; Diana Huynh; Anthony Jaworowski; Theodoros Kelesidis
Journal:  J Vis Exp       Date:  2017-10-12       Impact factor: 1.355

2.  Modification by isolevuglandins, highly reactive γ-ketoaldehydes, deleteriously alters high-density lipoprotein structure and function.

Authors:  Linda S May-Zhang; Valery Yermalitsky; Jiansheng Huang; Tiffany Pleasent; Mark S Borja; Michael N Oda; W Gray Jerome; Patricia G Yancey; MacRae F Linton; Sean S Davies
Journal:  J Biol Chem       Date:  2018-04-30       Impact factor: 5.157

3.  Human T lymphotropic virus type 1 and risk of cardiovascular disease: High-density lipoprotein dysfunction versus serum HDL-C concentrations.

Authors:  Sara Samadi; Samaneh Abolbashari; Zahra Meshkat; Amir Hooshang Mohammadpour; Theodoros Kelesidis; Aida Gholoobi; Mehrane Mehramiz; Mahla Tabadkani; Fatemeh Sadabadi; Razieh Dalirfardouei; Gordon A Ferns; Majid Ghayour-Mobarhan; Amir Avan
Journal:  Biofactors       Date:  2019-01-29       Impact factor: 6.113

4.  High-density lipoprotein lipid peroxidation as a molecular signature of the risk for developing cardiovascular disease: Results from MASHAD cohort.

Authors:  Sara Samadi; Mehrane Mehramiz; Theodoros Kelesidis; Majid Ghayour Mobarhan; Amir Hosein Sahebkar; Habibollah Esmaily; Mohsen Moohebati; Zahra Farjami; Gordon A Ferns; Amir Hooshang Mohammadpour; Amir Avan
Journal:  J Cell Physiol       Date:  2019-02-19       Impact factor: 6.384

5.  Dysfunctional high-density lipoprotein from HIV+ individuals promotes monocyte-derived foam cell formation in vitro.

Authors:  Thomas A Angelovich; Anna C Hearps; Michael N Oda; Mark S Borja; Diana Huynh; Stefanie Homann; Anthony Jaworowski; Theodoros Kelesidis
Journal:  AIDS       Date:  2017-11-13       Impact factor: 4.632

6.  Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332.

Authors:  Theodoros Kelesidis; Michelle A Kendall; Ann Danoff; Judith A Aberg; Judith S Currier; Ann Marie Schmidt
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

7.  Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions.

Authors:  Thomas A Angelovich; Anna C Hearps; Anna Maisa; Theodoros Kelesidis; Anthony Jaworowski
Journal:  J Vis Exp       Date:  2017-10-17       Impact factor: 1.424

8.  Greater IL-6, D-dimer, and ICAM-1 Levels Are Associated With Lower Small HDL Particle Concentration in the Multicenter AIDS Cohort Study.

Authors:  Sudipa Sarkar; Sabina Haberlen; Seamus Whelton; Edward E Schneider; Lawrence Kingsley; Frank Palella; Mallory D Witt; Theodoros Kelesidis; Annabelle Rodriguez; Wendy S Post; Todd T Brown
Journal:  Open Forum Infect Dis       Date:  2019-11-13       Impact factor: 4.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.